$0.200
-0.105 (-52.65%)收盘时
- High
- 0.200
- Open
- 0.155
- VWAP
- 0.18
- Vol
- 6.29M
- Mkt Cap
- 2.61M
- Low
- 0.141
- Amount
- 1.14M
- EV/EBITDA, TTM
- -0.55
IMAC Holdings, Inc. owns and manages health and wellness centers that delivers sports medicine, orthopedic care, and restorative joint and tissue therapies for movement restricting pain and neurodegenerative diseases. The Company provides movement, orthopedic and neurological therapies through its chain of Innovative Medical Advancements and Care (IMAC) Regeneration Centers. The Company, through its outpatient medical clinics, provide conservative, minimally invasive medical treatments to help patients with back pain, knee pain, joint pain, ligament and tendon damage, and other related soft tissue conditions. It operates through two business segments: outpatient medical centers and clinical research division. The Company's research division is conducting a Phase I clinical trial evaluating a mesenchymal stem cell therapy candidate for bradykinesia due to Parkinson’s disease. The Company operates approximately 10 outpatient medical clinics in five states in the United States.
估值指标
事件时间线
资讯
3.512-15GlobenewswireBackslash Security Wins 2025 Technology of the Year Award for AI Security Innovation
3.512-10GlobenewswireBackslash Launches MCP Security Solution to Enhance AI Development Security
7.509-10NewsfilterIgnite Proteomics Partners with Inova Health for Late-Stage Cancer Biomarker Research
- 9.002-24Newsfilter
Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference
- 9.002-10Newsfilter
Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response
BACK FAQ — answered by Alphio AI
IMAC Holdings, Inc. owns and manages health and wellness centers that delivers sports medicine, orthopedic care, and restorative joint and tissue therapies for movement restricting pain and neurodegenerative diseases. The Company provides movement, orthopedic and neurological therapies through its chain of Innovative Medical Advancements and Care (IMAC) Regeneration Centers. The Company, through its outpatient medical clinics, provide conservative, minimally invasive medical treatments to help patients with back pain, knee pain, joint pain, ligament and tendon damage, and other related soft tissue conditions. It operates through two business segments: outpatient medical centers and clinical research division. The Company's research division is conducting a Phase I clinical trial evaluating a mesenchymal stem cell therapy candidate for bradykinesia due to Parkinson’s disease. The Company operates approximately 10 outpatient medical clinics in five states in the United States. It operates in the Healthcare sector (SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC industry).
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。